Анауран

Quick links

Choose a section

Quick links to important sections

Advertisements

Анауран

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Анауран

What is Anauran? An Overview

Property Description
Active Ingredients Neomycin sulfate, Polymyxin B sulfate, Lidocaine hydrochloride
Form Sterile Ear Drop Solution
Pharmacological Class Combined Antibiotics and Local Anesthetic
Common Use Local treatment of bacterial ear infections and associated pain
Origin Synthetic

1. Anauran: An Overview of the Drug's Identity and Form

Anauran is a topical, fixed-combination medicine specifically designed for use in otology (ear care). It is supplied as a sterile ear drop solution, a formulation that allows precise, local application within the external auditory canal. This dosage form is widely utilized because it ensures the active ingredients are highly concentrated at the site of infection.

Anauran is classified as a prescription medicine intended for the local management of specific external ear conditions. This topical route is generally favored in clinical practice as it is recognized for maximizing local efficacy while enhancing safety.


2. What Type of Medicine is Anauran and What Is It Made Of?

Anauran belongs to the pharmacological class of combined antibiotics and local anesthetics. The medicine is entirely synthetic in origin and relies on the synergistic action of its three key active ingredients: Neomycin sulfate, Polymyxin B sulfate, and Lidocaine hydrochloride.

This specific fixed composition, featuring two broad-spectrum antibiotics and a potent local anesthetic, is what differentiates it from single-agent ear drops. The inclusion of Lidocaine specifically addresses acute ear pain, which is a well-established component of external otitis. Its function is to provide rapid symptomatic relief by acting as a local anesthetic.


3. General Therapeutic Role: Why is Anauran Prescribed?

The general therapeutic purpose of Anauran is to simultaneously treat local bacterial infections and alleviate associated pain and discomfort within the ear. It offers a targeted, comprehensive solution for acute external ear issues.

Anauran is typically utilized in scenarios where bacterial infection of the external auditory canal is confirmed or strongly suspected. A common use scenario involves managing inflammation and infection associated with otitis externa—often known as Swimmer's Ear—where its anti-infective and anesthetic properties provide crucial, localized treatment.

Advertisements

What side effects are possible with Анауран?

Possible Side Effects and Safety Information

Anauran is a multi-component otic preparation containing an aminoglycoside antibiotic (Neomycin), a polypeptide antibiotic (Polymyxin B), and a local anesthetic (Lidocaine).

Serious Safety Warning: Ototoxicity Risk

The most critical safety restriction is the contraindication for use in patients with a known or suspected perforated tympanic membrane. The Neomycin component can cause permanent sensorineural hearing loss (ototoxicity) if it gains access to the inner ear, which occurs when the eardrum is compromised. The risk of ototoxicity is also greater with prolonged use.

Adverse Reaction Category Examples & Notes
Local Reactions Irritation, burning sensation, itching, redness, or peeling of the skin within the external auditory canal. These are usually transient and may resolve after discontinuation.
Systemic Risk Potential for systemic effects (nephrotoxicity, neurotoxicity) from Neomycin and Polymyxin B if significant absorption occurs, particularly with prolonged therapy or a perforated eardrum.
Hypersensitivity Allergic reactions to any of the active ingredients or excipients (such as Benzalkonium chloride) may occur, requiring immediate discontinuation.

Safety Restrictions and Use Considerations

  • Duration of Use: Treatment should be limited (e.g., typically no more than 7 to 10 consecutive days) to minimize the risk of ototoxicity, nephrotoxicity, and the development of superinfections by drug-resistant microorganisms.
  • Pediatric Use: Use in infants and young children requires particular caution and medical supervision due to potential increased systemic absorption.
  • Pregnancy and Lactation: The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, due to the ototoxicity potential of the aminoglycoside component.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this topical preparation is generally associated with accidental ingestion or extensive systemic absorption, such as through a perforated tympanic membrane. The official regulatory profile is defined by the toxic effects of its three active ingredients.

Documented Overdose Manifestations
Cardioneurotoxicity: Manifestations may include confusion, dizziness, tinnitus, seizures, slurred speech, low blood pressure (hypotension), and severe cardiovascular events.
Organ Toxicity: Risk of permanent sensorineural hearing loss and signs of potential kidney damage (e.g., changes in urination) linked to the antibiotic components.

Severe Outcomes and Required Actions

The toxicity profile is classified as potentially life-threatening due to the documented risks of cardiac arrest from the anesthetic component and irreversible auditory damage.

  • Seek Immediate Medical Attention: Contact a Poison Control Center (e.g., 1-800-222-1222) immediately upon suspected overdose or accidental ingestion.
  • Call Emergency Services (e.g., 911): Must be called immediately if the person is collapsed, is having a seizure, or has severe trouble breathing.

Overdose Management Notes

Management is typically symptomatic and supportive, requiring intensive care and continuous hospital monitoring. Specific procedural treatments, such as intravenous lipid emulsion therapy, are officially recognized for severe systemic toxicity from the Lidocaine component. The risk of toxicity is increased in patients with impaired renal function, infants, and the elderly.

Advertisements

Therapeutic Uses of Анауран

Анауран, which is a combination of antibiotics and a local anesthetic, is commonly used to help manage ear conditions presenting with systemic or localized discomfort and symptoms related to inflammatory or irritative states. The therapeutic domain is applied in addressing conditions presenting with acute or disruptive episodes.

The medication is considered relevant for easing symptom clusters that may become intense or disruptive in clinical scenarios involving conditions where symptoms may intensify temporarily, such as during flare-ups of superficial bacterial infections of the external auditory canal. The combination is applied across domains where additional symptomatic support is needed.

The combined action of the ingredients is used in situations involving certain distressing symptoms, generally assisting with easing symptoms related to inflammatory or irritative states. This supports the patient during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods. The medication provides supportive relief when symptoms interfere with routine activities and assists with maintaining functional stability in scenarios where short-term symptom stabilization is important.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. DailyMed (NIH/FDA) product label
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Анауран

The eligibility for using Анауран ear drops is strictly defined by regulatory documents, focusing on patient status, age, and existing physical conditions. Use is permitted for adults and older adults without any specific contraindications.

Classification Who Must Not Use (Contraindicated)
Physical Condition Patients with a perforated (ruptured) eardrum.
Immunological Status Individuals with a known hypersensitivity or allergy to Neomycin, Polymyxin B, Lidocaine, or related compounds, including a history of allergic reactions to other topical aminoglycosides.
Etiology Patients whose ear disorder is due to a viral infection (e.g., Herpes simplex) of the external auditory canal.

Age- and Condition-Based Restrictions

Official labeling imposes specific restrictions based on age and physiological status:

  • Infants: Use in children under one year of age is highly restricted and only permitted under the direct control of a physician.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is restricted to cases of clear medical need and must be supervised by a physician, as safety is not definitively established in these populations.
  • Duration: Therapy is restricted to a short course and generally should not exceed 10 consecutive days.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Anauran (Neomycin sulfate, Polymyxin B sulfate, and Lidocaine hydrochloride) is based on the established potential for systemic absorption of its components, particularly if the eardrum is perforated. The official regulatory cautions focus on the risks associated with the components becoming systemically available.


Official Interaction Restrictions

Interaction Type Interacting Substance/Class Official Regulatory Statement
Additive Toxicity Risk Drugs with neurotoxic, ototoxic, or nephrotoxic effects General avoidance of concomitant or sequential use is advised due to the risk of additive systemic toxicity from the Neomycin and Polymyxin B components.
Pharmacodynamic Neuromuscular blocking agents (e.g., suxamethonium) Co-administration may intensify and prolong the respiratory depressant effects.
Pharmacokinetic Cimetidine or beta-adrenoceptor blocking agents May reduce the systemic clearance of the Lidocaine component, increasing its systemic concentration upon absorption.
Additive Toxic Effects Other local anesthetics or amide-type anti-arrhythmics Use results in additive systemic toxic effects from the Lidocaine component.

Population-Specific Interaction Note

In patients with impaired renal function, the plasma clearance of the Neomycin component is reduced. This condition may increase the potential for systemic toxicity and the clinical relevance of systemic interaction risks if significant absorption occurs, according to official prescribing information.

Advertisements

Mechanism of Action

Dual Mechanisms of Bacterial Destruction

This domain covers the synergistic mechanisms of Neomycin and Polymyxin B for bacterial destruction. Neomycin targets the bacterial 30S ribosomal subunit, disrupting the protein synthesis pathway through translational error. Polymyxin B simultaneously destabilizes the bacterial cellular and outer membranes through pore formation and electrostatic interaction. This mechanism enhances the cell's permeability, facilitating the uptake of Neomycin to its intracellular target. This combined mechanistic assault leads to bacterial cell death and microbial population reduction.

Localized Blockade of Sensory Signaling

This domain focuses on the mechanism of Lidocaine, which modulates the peripheral sensory pathway to interrupt nerve impulse transmission. Lidocaine operates by binding within and blocking the voltage-gated sodium channels (Nav) in nerve membranes. This prevents the sodium influx required to generate an electrical action potential. The resulting inhibition of nerve impulse conduction leads to local electrical inexcitability in the affected neurons.

Mechanism Limitations

The underlying mechanism is highly target-specific and is ineffective against viral or fungal organisms, which lack the necessary ribosomal or membranous targets. Furthermore, the molecular potential of Neomycin to accumulate in non-bacterial cells (specifically cochlear hair cells) imposes a physiological constraint on the application, potentially leading to off-target cellular accumulation.

Advertisements

Dosage and Administration Information

How to Use Anauran: Official Administration Guidelines

Anauran is a combination topical solution intended for strictly localized application, following specific parameters for otic preparations containing neomycin, polymyxin B, and a local anesthetic.


Administration Scope

The approved route of administration is Auricular (Otic) Instillation. This restricts the medicine's use exclusively to the external ear canal.

The dosing schedule typically involves administering a specific number of drops into the affected ear, based on population. The standard regimen specifies four drops for adults, while a lower volume of three drops is specified for infants and children. Administration frequency is defined as three or four times daily.


Procedural and Time Constraints

The usage protocol includes mandatory procedural steps to ensure proper delivery of the solution. The guidance requires that the external auditory canal first be thoroughly cleansed and dried. To enhance penetration, the medicine should be warmed by holding the bottle in the hand for one to two minutes prior to use.

Upon instillation, the patient is required to lie with the affected ear facing upward and maintain this position for five minutes. This measure ensures the drops fully contact the site of application. A major use-context constraint is the duration of use, which must be strictly limited to 10 consecutive days.

These instructions define the standardized, time-bound procedure for the medicine, focusing on a consistent dose, a fixed daily frequency, and precise application steps.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Анауран

This section provides a neutral, non-advisory summary of the clinical research and scientific studies available for the topical antibiotic and anesthetic combination in Анауран.


Evidence for Use in Acute Bacterial Otitis Externa

Research exploring the use of this combination involved short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time for acute bacterial infections of the external ear canal, often called Swimmer's Ear. The studies primarily focused on adults with uncomplicated infection, while some large observational reports also included data on outcomes for children.

The main goal of these studies was to observe outcomes related to changes in clinical signs (such as redness and discharge) and to monitor physiological strain or stress related to the infection. Furthermore, research also monitored patient-reported outcomes describing perceived discomfort, specifically ear pain (otalgia). Studies reported measurements of clinical resolution rates at defined short-term intervals, typically 7 to 10 days. The reported outcomes were short-term and focused on measuring changes observed during the study period.


Research on Symptomatic Relief and Comparative Outcomes

The combination includes a local anesthetic (Lidocaine), and research has been applied in studies examining symptom intensity or variability. Specifically, research has explored the onset and duration of changes in pain intensity, in studies that included comparisons with other topical treatments that may not contain a local anesthetic component. Studies monitored how symptoms evolved in the observed populations, and research describes the time to change in pain scores, and some studies reported patterns related to timing when compared to certain alternative treatments.


What Remains Uncertain About the Research Base

The research exploring short-term symptom changes covers a range of trial types, but the research quality and quantity vary across different types of otitis externa (e.g., purely bacterial versus mixed). Long-term effects are not fully established, and evidence is limited regarding outcomes related to systemic or functional imbalance beyond the acute infectious phase. Sample sizes were modest in some specific trials, and results apply only to the populations studied. Research provides context but not individual predictions about symptom recurrence or the maintenance of functional stability months after the acute episode has cleared.

Key Studies & References

  1. Otitis Externa - StatPearls (Source covering evidence strength, duration, and comparative efficacy)
  2. Anauran Ear drops EU Regulatory Product Information (Source for studied populations and acute/chronic indications)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Анауран (FAQ)

Q: Is Анауран safe to use if I have an ear tube (tympanostomy tube)?

Regulatory documents state that this medicine is strictly prohibited if you have a known or suspected perforated eardrum. An ear tube (tympanostomy tube) creates an open path to the middle ear. The official contraindication against use with a perforated eardrum is based on the potential for the Neomycin component to cause irreversible hearing damage if it gains access to the inner ear.

Q: Does Анауран have any known interaction with common over-the-counter pain relievers?

Official information advises general avoidance of using this medicine at the same time as any other drug known to potentially affect the kidneys (nephrotoxic) or hearing/balance (ototoxic). This caution is due to the potential for increased systemic toxicity if the Neomycin component is absorbed. It is important to discuss all non-prescription pain relievers with a healthcare professional to assess potential risks.

Q: What should I do if I forget to use the drops at the scheduled time?

Official patient guidance indicates that if a dose is missed, administering it as soon as possible is the general procedure. However, if it is nearly time for the next scheduled dose, the official guidance is to skip the missed dose and return to your regular schedule. It is specifically not advised to double the dose to make up for the missed application.

Q: Can I use Анауран for pain relief even if I don't have an infection?

Official regulatory indications define the use of this medicine for the local treatment of acute bacterial external otitis (outer ear infection). Its therapeutic purpose is to simultaneously treat the infection and alleviate associated pain. The official therapeutic indication does not include use for pain relief alone.

Q: What are the ingredients in Анауран besides the active medicines?

Official documents detail both the active and inactive ingredients, known as excipients. In addition to the three active medicines, the solution typically contains inactive substances such as water, propylene glycol, and a preservative like Benzalkonium chloride. These components are included to maintain the product's stability and assist in the proper delivery of the solution.

Q: How quickly does Анауран get absorbed into the body after application?

Official product information regarding topical ear drops generally does not define the exact rate of systemic absorption (how quickly it enters the bloodstream). Instead, official documentation focuses on the fact that systemic absorption risk increases significantly if the eardrum is perforated or if the medicine is used for prolonged periods.

Q: If I stop using Анауран too soon, can the infection come back worse?

Official guidance emphasizes completing the full duration of treatment as prescribed. Premature discontinuation risks an incomplete course of treatment. Regulatory principles emphasize completing the prescribed duration to help prevent the infection from returning and to minimize the potential for developing drug-resistant bacteria.

Q: Does sun exposure have any effect on how Анауран works?

Official warnings for products containing Neomycin generally state that excessive exposure to sunlight or UV light should be avoided during treatment. This is because topical application of Neomycin can sometimes lead to photosensitivity reactions, which means the skin may become unusually sensitive to sunlight.

Q: Can I use Анауран in both ears even if only one is infected?

Official dosing instructions specify application to the affected ear. Regulatory guidance does not provide information supporting the use of the medicine in the ear that is not infected.

Q: What is the shelf life of Анауран after the bottle has been opened?

The official labeling specifies the shelf life of the medicine once it has been opened (often called 'in-use' stability). This time period, which can be short (e.g., 14 to 30 days), indicates when the medicine must be discarded, even if some drops remain in the bottle.

Q: Can I go swimming while I am using Анауран ear drops?

Official instructions emphasize the importance of keeping the external auditory canal thoroughly cleansed and dried during the treatment period. Activities that introduce moisture, such as swimming, are generally not compatible with the requirement to keep the ear canal thoroughly dried.

Q: Does Анауран have any potential for misuse or dependence?

Official drug information provided by regulatory agencies indicates that no evidence of drug abuse or dependence has been reported or established with the use of this specific combination product.

Q: What happens if a child accidentally swallows a small amount of Анауран drops?

Official documents state that due to the small volume and localized nature of the medicine, accidental swallowing is unlikely to lead to serious systemic effects (effects throughout the body). However, as a precaution, immediate contact with a poison control center is always advised following any accidental ingestion.

Q: Can I use earplugs while I am being treated with Анауран?

Official administration instructions require the drops to remain in contact with the affected area for a specific period after application. The use of foreign objects like earplugs or cotton is not addressed in official guidelines and may potentially interfere with the medicine's local action or intended contact time.

Q: What are the different strengths or concentrations available for Анауран?

The official label clearly states the specific concentration (mg/mL or units/mL) of each active ingredient in the solution. This medicine is defined as a fixed combination, meaning the amount of Neomycin sulfate, Polymyxin B sulfate, and Lidocaine hydrochloride is standardized in the formulation.

Q: Are there any dietary restrictions when using Анауран?

Official drug interaction information specifies that there are no known restrictions regarding food or diet when you are using this topical medicine. Its localized application means systemic absorption is generally low under normal use conditions.

Q: Is it safe to use Анауран drops if I wear hearing aids?

Official precautions typically advise removing hearing aids before you instill any ear drops into the ear canal. Official precautions recommend that the drops be allowed to fully drain or dry completely before re-inserting the hearing aid, as residual moisture could potentially damage the device.

Q: How long does it usually take to feel some relief after starting Анауран?

Studies and official information examining the local anesthetic component (Lidocaine) indicate a generally rapid onset of pain-relieving effects. The change in perceived discomfort is often reported to begin within minutes after the application of the drops.

Q: Is Анауран effective for an outer ear infection only, or can it help with middle ear issues too?

According to the official therapeutic indication, this medicine is strictly for the treatment of acute bacterial external otitis (an outer ear infection). It is not indicated for treating middle ear infections (otitis media) unless that specific use is secondary to surgical treatment and approved by a physician.

Q: Is it true that Анауран is only prescribed for certain types of bacteria?

The combination is defined in regulatory labeling as active against a specific spectrum of bacteria. This typically includes certain strains of common pathogens like Staphylococcus and Pseudomonas that are often responsible for external ear infections. As a fixed combination, its effectiveness is limited to the bacterial types listed in its defined spectrum.

Q: Can using Анауран drops make me dizzy or affect my balance?

Official labeling specifically lists dizziness (vertigo) as a potential adverse reaction or symptom. This concern is tied to the risk of ototoxicity (potential inner ear damage) if the medicine gains systemic access, for instance, through a perforated eardrum.

Q: What are the signs that Анауран is actually starting to work?

Clinical trials for this combination monitored patient outcomes related to a reduction in pain scores and improvement in visible clinical signs. These observed clinical signs may serve as indicators of the medicine’s expected action.

Q: Is it common for people to get a fungal infection after stopping Анауран (secondary infection concern)?

Official warnings include the risk of superinfection by non-susceptible organisms, including fungi, especially with prolonged or repeated courses of antibiotic therapy. This is a known possibility when using topical antibiotics, as the medicine can reduce the normal bacterial flora.

Q: What is the proper way to tilt the head when applying Анауран drops?

Official patient instructions advise tilting the head to the side or lying down so the affected ear is facing upward. This position is recommended to help ensure the drops flow into the ear canal and remain in contact with the affected area for the specified time.

Q: Does Анауран treat the inflammation or just the infection?

Official guidance notes that this medicine is used to treat the bacterial infection and alleviate associated pain. While it does not contain a specific anti-inflammatory agent, successfully eliminating the underlying bacterial cause is expected to result in a reduction of infection-related inflammation and swelling.

Q: Are the antibiotics in Анауран the same as those used in oral medications?

Official documents note that the active antibiotic ingredients are used in various dosage forms. For example, Neomycin is used in some oral formulations (often to prepare the gut for surgery), while Polymyxin B is less commonly used orally. This ear drop solution is formulated specifically for localized application.

Q: Is Анауран considered a 'broad-spectrum' antibiotic ear drop?

The official pharmacology section characterizes the two antibiotics in this combination as having an antimicrobial spectrum that is broad relative to the usual pathogens causing external otitis. This means they are effective against a wide range of the most common bacteria responsible for this type of ear infection.

Q: What is the risk of an antibiotic resistance developing with Анауран?

Official labeling provides explicit warnings about the general risk associated with antibiotic use. The label includes warnings that prolonged use, or use outside the recommended duration, carries the potential to select for and cause the overgrowth of antibiotic-resistant organisms.

Q: Can I use other topical ear preparations at the same time as Анауран?

Official documents focus primarily on systemic drug interactions and do not specifically advise on the use of other topical ear preparations at the same time. The use of other drops or solutions could potentially interfere with the intended effectiveness or proper contact time of this medicine.

Advertisements

How should Анауран be stored and disposed of?

How to Store and Dispose of Анауран?

The storage and disposal of Анауран (neomycin sulfate, polymyxin B sulfate, and lidocaine hydrochloride) are governed by specific regulatory requirements to maintain product stability and safety.

Official Storage Requirements

The product must be stored at a temperature not exceeding 25 C. To maintain product integrity, it is required to store the medicine in the original container for protection from light. The container must also be kept tightly closed to prevent moisture exposure. For safety, the medicine must be kept out of the reach and sight of children.

Disposal Instructions

Any unused or expired Анауран must be disposed of in accordance with local requirements for pharmaceutical waste. The regulatory labeling explicitly states that the medicine should not be discarded via wastewater or standard household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Анауран found in:

A-Z Index: